Literature DB >> 2936838

Endogenous thymidine and hypoxanthine are a source of error in evaluating methotrexate cytotoxicity by clonogenic assays using undialyzed fetal bovine serum.

A F Sobrero, J R Bertino.   

Abstract

None of 13 fresh human tumor samples of various histology cloned in a two-layer agar culture system with 20% undialyzed fetal bovine serum (FBS) showed sensitivity to three antifolates, methotrexate (MTX), trimetrexate and 5,8-dideazaisofolic acid (IAHQ), even after continuous exposure to the highest concentrations (100 microM) for 21 days. In order to investigate this lack of antifolate drug effect, we compared the toxicity of continuous MTX exposure in the human colon carcinoma cell line HCT-8, cloned in a thymidineless medium (RPMI 1640) supplemented with 10% horse serum (HS), 10% fetal bovine serum (FBS), 20% FBS or 20% dialyzed FBS. In the presence of native FBS, when the minimum clone size was set at 30 cells/colony, the survival of HCT-8 cells reached a plateau at approximately 60% of untreated control after exposure to MTX concentrations between 0.1 microM and 100 microM. Only when the minimum clone size was set at 2 X 10(3) cells/colony was the sensitivity of HCT-8 cells to the antimetabolite comparable to that obtained in HS or dialyzed FBS (ED50 values in the range of 0.01 microM). MTX protection experiments indicated that even very small concentrations of thymidine and hypoxanthine together were sufficient to reproduce the pattern of sensitivity to MTX observed under culture conditions with undialyzed FBS. We conclude that for a proper evaluation of MTX cytotoxicity in clonogenic assays, dialyzed FBS and thymidine-less media should be employed; if native FBS is an absolute requirement for growth, only very large colonies (at least 10 cell divisions) should be scored.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2936838     DOI: 10.1002/stem.5530040106

Source DB:  PubMed          Journal:  Int J Cell Cloning        ISSN: 0737-1454


  6 in total

1.  Methotrexate cytotoxicity determination using the MTT assay following enzymatic depletion of thymidine and hypoxanthine.

Authors:  M Haber; J Madafiglio; M D Norris
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 2.  Methotrexate delivery via folate targeted dendrimer-based nanotherapeutic platform.

Authors:  István J Majoros; Christopher R Williams; Andrew Becker; James R Baker
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2009 Sep-Oct

3.  Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; T Morikage; Y Fujiwara; N Saijo
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

4.  Modulation of antifolate cytotoxicity by metabolites from dying cells in a lymphocyte clonal assay.

Authors:  J M Hughes; A deFazio; M H Tattersall
Journal:  Br J Cancer       Date:  1988-05       Impact factor: 7.640

5.  Potentiation of methotrexate lymphocytotoxicity in vitro by inhibitors of nucleoside transport.

Authors:  J M Hughes; M H Tattersall
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

6.  Evaluation of the relative cytotoxic effects of anticancer agents in serum-supplemented versus serum-free media using a tetrazolium colorimetric assay.

Authors:  C M Tsai; R P Perng; K T Chang; D Venzon; A F Gazdar
Journal:  Jpn J Cancer Res       Date:  1996-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.